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Gene expressionApolipoprotein A5 (APOA5) gene plays a key role in plasma triglyceride (TG)metabolism, and shows the involve-
ment in coronary artery disease (CAD). A set of single nucleotide polymorphisms around the APOA5 gene was
identiﬁed to be associatedwith plasma TG levels. It is of biological and clinical importance to discern the genuine
genetic determinants. A polymorphism in 3′ untranslated region of the APOA5 gene, rs2266788, is deserving of
investigation for suggestive clues from the association in multiple independent studies. In this study,
rs2266788was genotyped in 3222 unrelated subjects consisting of 2062 CAD cases and 1160 controls. The statis-
tical analyses indicated that theminor C allele of rs2266788was signiﬁcantly associatedwith elevated plasma TG
levels and higher CAD risk. In normal human liver tissues, comparison of global APOA5 mRNA levels among
genotypes and allelic expression imbalance analysis showed the decreased gene expression for the C allele.
Luciferase assays conﬁrmed a concordant result that transcriptional activity was lowered for the C allele com-
pared with the T allele in four cell lines. Multiple lines of evidence in our study supported that rs2266788 was
causally associated with plasma TG levels conferring CAD risk in Han Chinese population owing to a cis-acting
effect to the APOA5 gene expression.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Plasma triglyceride (TG) levels are usually related to the incidence of
multiple cardiovascular diseases, type 2 diabetes mellitus, concomitant
metabolic abnormalities of these disorders, and even the efﬁcacy of
anti-hyperlipidemic treatment [1]. Elevated plasma TG levels had been
recognized as an epidemiological risk to premature coronary artery
disease (CAD) [2–5]. Comprehensive understanding of the factors
responsible for variation in plasma TG levels is of clinical and biological
importance.
Plasma TG concentration is a complex polygenic trait. The studies for
genetic determinants of TG metabolism have been extensively carried
out and found many genomic loci implicated in regulation of TGoratory of Health and Disease
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gying@geneskies.com
.sh.cn (B. Wang),
u), wangyi@chgc.sh.cn
h.cn (J. Shi),concentrations. In total, nearly 40 loci were identiﬁed signiﬁcantly asso-
ciated with TG levels by large scale genome-wide association studies
(GWAS) of blood lipids, candidate target studies and animal model
studies [6–8]. Notably, a set of associations were identiﬁed in the
11q23.3 region harboring the APOA1/C3/A4/A5 gene cluster, which has
been well documented for its involvement in blood lipid metabolism
[9]. This locus was evaluated to account for the largest share of genetic
contribution to plasma TG variance within human population [10].
Apolipoprotein A5 (APOA5) gene (MIM 606368), encodes an ex-
changeable apoprotein APOAV, which is exclusively expressed in
human liver tissue, and secretes into plasma to play a key role in plasma
TG metabolism [11]. The APOA5 gene was a more recently discovered
member in the gene cluster through orthologous sequence comparison
between human and mouse [12]. Genetically modiﬁed mice gave the
compelling evidence that a strikingly inverse relationship between
apoAV content and plasma TG levels was identiﬁed in transgenic and
knockout mouse models [12,13]. The effect of sequence variations
around the APOA5 gene in humans was also extensively investigated
in diverse ethnic groups. Numerous single nucleotide polymorphisms
(SNPs) along the APOA1/C3/A4/A5 gene cluster were found with strong
evidence of association with blood lipids and cardiovascular diseases.
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have been ill-deﬁned against the proxy SNPs, and the underlyingmech-
anisms to accounting for the statistic associations are much less clear.
Hence, it is challenging to recognize causative variants modulating TG
levels, and even the potential implication in CAD development.
A SNP in the 3′ untranslated region (UTR) of APOA5, rs2266788, was
early found to be associated with plasma TG concentrations across
multiple ethnic groups [14,15]. This ﬁndingwas substantiated by strong
evidence from a GWAS of European cohorts including type 2 diabetes
patients [16]. Whereas, this SNP was usually less appreciated for a
promoter SNP rs662799 (−1131TNC) with better accountability of the
possible effect [14,15], or it received less attention than the lead SNPs
with the highest signiﬁcance in nearby regions, although its association
was also strong in the statistic results (P= 5.763 × 10−30 for TG; P=
8.38 × 10−7 for CAD) [17,18]. Critically, the association of the underrep-
resented SNP rs2266788 was ambiguous in studies of Chinese
populations [19]. A nucleotide conversion at rs2266788 was in silico
predicted to disrupt an Oct-1 transcription factor binding site, but did
not cause signiﬁcant alteration in luciferase expression in vitro [20]. Par-
adoxically, the effects of different combinations of rs662799, rs651821
(−3ANG) and rs2266788 on luciferase activity suggested a contributing
effect of rs2266788 [21]. Then, the authenticity of its functionality is
deserving of inspection.
We sought to ascertain whether rs2266788 is associated with plas-
ma TG levels in Han Chinese population, and whether it is a proxy SNP
or a true causative variant. In addition, we appraised the etiologic role
of rs2266788 in CAD incidence. It is helpful and necessary to pinpoint
the actual genetic determinants for the prediction of dyslipidemia risk,
and the prevention against atherosclerosis to CAD endpoint.
2. Material and methods
2.1. Ethics statement
All participants gave written informed consent. The approval to
undertake this study was granted by the Ethics Review Committee of
the Chinese National Human Genome Center at Shanghai, and it was
conducted according to the Declaration of Helsinki Principles. The
samples and the collected information were made anonymous prior to
testing.
2.2. Population samples and SNP genotyping
Blood samples were collected from 3222 unrelated individuals with
self-reported origin of central Han Chinese (Shanghai and the neighbor-
ing provinces), consisting of 2062 CAD cases and 1160 controls free of
atherosclerosis. The demographic and clinic characteristics of the sub-
jects are summarized in Table 1. Coronary atherosclerosis was diag-
nosed on the basis of coronary angiography. A consensus diagnosis
was performed by two experienced doctors. CAD caseswere document-
ed by angiographic evidence of 75% stenosis of at least one major coro-
nary artery, or by a history of prior angioplasty, coronary artery bypassTable 1
Clinical characteristics of the study subjects.
Characteristics All subjects Controls Cases
Male/female 1986/1236 568/592 1418/644
Age (years) 63.52 ± 10.48 60.55 ± 9.96 65.19 ± 10.40
Cases/controls 2062/1160 – –
TG (mmol/L) 1.77 ± 1.24 1.66 ± 0.96 1.83 ± 1.37
TC (mmol/L) 4.68 ± 1.99 4.58 ± 1.12 4.70 ± 1.28
HDLC (mmol/L) 1.20 ± 0.40 1.25 ± 0.40 1.17 ± 0.42
LDLC (mmol/L) 2.88 ± 1.57 2.74 ± 1.12 2.99 ± 2.54
TG, triglyceride; TC, total cholesterol; HDLC, high-density lipoprotein-cholesterol; LDLC,
low-density lipoprotein-cholesterol.
Data are shown as mean ± standard deviation.grafting, and coronary angioplasty surgery. Controls were proven with-
out coronary stenosis and myocardial infarction. Blood lipid proﬁles
were determined using freshly separated plasma. Total cholesterol
(TC), high-density lipoprotein-cholesterol (HDLC) and TG were mea-
sured by a one-step enzymatic method (Span Diagnostics and Erba
Mannheim, Germany). The coefﬁcient of variation for these measure-
ments was less than 1.6% low-density lipoprotein-cholesterol (LDLC)
was calculated by the Friedewald equation up to TGb 4.5 mmol/l. Geno-
mic DNA was isolated from whole blood using FlexiGene DNA Kit
(Qiagen, Valencia, CA, USA). The polymorphism rs2266788 were geno-
typed by TaqMan method on ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, Inc., Foster City, CA), and allelic discrimi-
nation was performed with Sequence Detection Systems (SDS) 2.0
software (Applied Biosystems). Primers are listed in Table S1.
2.3. Liver tissue, gene expression and allelic expression imbalance
A total of 89normal human liver biopsy sampleswere collected from
unrelated Han Chinese transplant donors and stored in RNAlater
(Sigma-Aldrich) at−70 °C. Subjects, ranging from 30 to 45 years old,
were morphologically normal and negative for human immunodeﬁ-
ciency virus and hepatitis. No drugs, alcohol and cigarettes were con-
sumed by subjects for at least 30 days prior to surgery. Genomic DNA
and total RNAwere simultaneously extracted from the liver tissue sam-
ples using QIAGEN AllPrep DNA/RNA Mini Kit according to the
manufacturer's instructions. The quality of each RNA sample was con-
ﬁrmed by the presence of strong 18S and 28S bands following agarose
gel electrophoresis. Total RNAwas treatedwith RNase-free DNase to re-
move residual genomic DNA. First-strand cDNA was synthesized using
M-MLV Reverse Transcriptase (Promega) in a sterile 25 μl volume con-
taining 0.5 μg of total RNA, 0.5 μM dNTPs, 1 mM Oligo(dT)15, 5 μM ran-
dom nonamer primers and 20 U ribonuclease inhibitor (Takara).
APOA5mRNAexpression levelwasquantiﬁedby real-timePCRusing
SYBR Green RT-PCR kit (Takara) on ABI PRISM 7900HT Sequence Detec-
tion System. The house-keeping gene, Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) gene,wasused as an internal control. Primers are
listed in Table S1. Relative expression levels were calculated using the
standard curve method in SDS 2.0 software, and all assays were
performed in triplicate for each sample. Quantiﬁcation of gene expres-
sion was presented as the ratio of APOA5 to GAPDH.
Allelic expression imbalance (AEI) wasmeasured by parallel quanti-
tative genotyping of heterozygous SNPs at the gene transcription level,
and genomic DNA was used as a comparative reference to calibrate in-
herent measuring bias in favor of certain allele. All liver samples were
genotyped, and heterozygotes were selected to determine AEI levels.
SNaPshot method was used to discriminate alleles for both genomic
DNA and mRNA. Primers are listed in Table S1. AEI was measured as
the ratio of the ﬂuorescence signals from the two alleles. The procedure
was described in more detail by Shou et al. [22].
2.4. Plasmid constructs, host cell culture, and luciferase reporter assays
To construct luciferase reporter plasmids, fragments of the entire
APOA5 3′ UTR of different rs2266788 alleles were cloned into the
pGL3-Promoter luciferase reporter vector (Promega, Madison, WI).
The target fragments were ampliﬁed by PCR from genomic DNA tem-
plates with known genotype, and then inserted into the XbaI restriction
site of the vector, downstreamof the luc+ transcriptional unit (Fig. 3A).
The PCR primers are listed in Table S1. The recombinant constructswere
veriﬁed by direct sequencing.
Human hepatoma cell lines BEL-7402, BEL-7405, Huh7 and
HepG2 were used for transient transfection to assay luciferase re-
porter activity. RPMI1640 medium for BEL-7402 and BEL-7405,
Dulbecco's modiﬁed Eagle's medium (DMEM) for Huh7, and
minimal essential Eagle's medium (MEM) for HepG2 were used in
cell culture, supplemented with 10% fetal bovine serum (FBS),
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ed into 24-well plates at a density of 1 × 105 per well. After over-
night culture, cells were co-transfected with 0.4 μg of each allele
reporter constructs and 0.03 μg Renilla luciferase pRL-SV40 plasmid
as an internal control per well, using jetPEI transfection reagent.
Cells were harvested 42 h after transfection and lysed with Passive
Lysis Buffer (Promega) for subsequent reporter gene assays. Each
assay was performed in quadruplicate. The lysate was used to detect
luciferase activity on Microlumat Plus LB 96 V luminometer
(Berthold Technologies, Bad Wildbach, Germany) with Dual-
Luciferase Reporter Assay System (Promega).
2.5. Statistical analysis
Deviation from Hardy–Weinberg equilibrium (HWE) was assessed
by the chi-square test (1 df). Actual measures of plasma lipid traits
were statistically transformed (TG and HDLC: log transformed; LDLC:
square root transformed; TC: natural log transformed) to approximate
a normal distribution and obtain equality of variance [23] (Fig. S1). Sta-
tistical association analyseswere performed using programPLINK v1.07
(http://pngu.mgh.harvard.edu/~purcell/plink/). A linear regression
model was applied to assess the association with quantitative measures
of blood lipid traits under an additive genetic model, with adjustments
for age, sex and CAD status. The genotypic distribution between cases
and controls was compared by Cochran–Armitage trend test. The asso-
ciations between the genotypes and CAD risk, odds ratios (ORs) and
95% conﬁdence intervals (CIs) were evaluated using binary logistic re-
gression model with adjustments for gender, age, and TG level. The
Haploview program [24] was used to analyze pairwise linkage disequi-
librium (LD) with data extracted from 1000 Genomes datasets (http://
www.1000genomes.org/home). The gene expression difference
was compared by one-way ANOVA with Tukey's post hoc test using
SPSS 13.0 package (SPSS Inc., Chicago, IL). Values are expressed as
mean ± standard deviation (SD), and P b 0.05 was considered
signiﬁcant.
3. Results
3.1. Association of the polymorphism with plasma TG levels and coronary
atherosclerosis
The SNP rs2266788 (C/T) was genotyped in all 3222 Han Chinese in-
dividuals. No deviation from HWE was shown for this SNP in controls or
all samples (P N 0.05) (Table S2). The frequency of the minor allele C in
our samples was 23.5%, which is fully concordant with the frequency
(22.1%) in the CHB (Han Chinese in Beijing) population from HapMap
III (http://hapmap.ncbi.nlm.nih.gov/). Through multiple linear regression
analysis, strong evidence was identiﬁed for a signiﬁcant association be-
tween polymorphism rs2266788 (P = 1.02 × 10−13) and plasma TG
levels in the Han Chinese population (Table 2). The copy number of the
C allele was associatedwith increased TG concentration (Fig. S2). Consid-
ering the signiﬁcant difference in TG levels (Table S3) between the case
and control groups (P b 0.001) and between two gender cohortsTable 2
Associations of rs2266788 with plasma TG levels in the Han Chinese population.
Sample N Beta (95% CI)
Total 3222 0.051 (0.037–0.064)
Controls 1160 0.059 (0.037–0.081)
Cases 2062 0.045 (0.028–0.062)
Females 1236 0.052 (0.031–0.073)
Males 1986 0.051 (0.033–0.068)
CI, conﬁdence interval; CAD, coronary artery disease.
⁎ Statistics inmultiple linear regressionmodelswith adjustments for age, sex, and CAD status
in female and male cohorts).(P b 0.01), age, sex, and CAD status were included as covariates in
multiple linear regressionmodels. The signiﬁcance of associationbetween
the variant and TG levels remained strong (P=5.17 × 10−13), exceeding
the genome-wide signiﬁcance cut-off (P b 5×10−8). In stratiﬁed analyses
(Table 2), the association of this polymorphism with plasma TG
concentration was overall signiﬁcant in controls (P = 1.01 × 10−7),
cases (P = 3.48 × 10−7), females (P = 4.68 × 10−6), and males (P =
6.60 × 10−9). The association between rs2266788 and other blood lipids
was also tested (Table S4). The SNP was associated with plasma HDLC
levels (P= 0.005)with amodest effect size, but the direction of the effect
was inverse to that of the effect on plasma TG levels. This result is consis-
tentwith the previous observation that plasmaAPOAV levels are positive-
ly correlated with HDLC and negatively correlated with TG concentration
[25].
The relevance of rs2266788 to CAD incidence was also investigated.
Cochran–Armitage trend tests were performed in the total samples, in
females, and in males (Table 3). The association was nearly signiﬁcant
(OR = 1.119, 95% CI 0.992–1.263, Ptrend = 0.066) in the total samples,
suggesting the susceptibility of this variant to CAD development, and a
possible risk factor from TG-raising C allele. The minor C allele was sig-
niﬁcantly associated with an increased CAD risk in the female cohort
(OR = 1.267, 95% CI 1.044–1.523, Ptrend = 0.015), but not in the male
cohort. In logistic regression analyses (Table 4), the association of
rs2266788 with CAD became signiﬁcant after adjustment for age and
sex in the total samples (OR = 1.151, 95% CI 1.012–1.309, P= 0.033).
The association became stronger and theminor C allele conferred a larg-
er risk in females (OR= 1.397, 95% CI 1.139–1.714, P= 0.001) after in-
cluding age as a covariate in the logistic model. Noticeably, TG levels
were signiﬁcantly higher in females than in males among our subjects
(Table S3). For a stronger predisposition of elevated TG to CAD, the ge-
netic effect seemed more signiﬁcant in TG-higher subjects. Similarly, in
an investigation of rs2075291 (c.553GNT; p.185GlyNCys) among Asian-
American hypertriglyceridemia patients, differences in plasma lipid
levels across genotypes were greater in the high-TG group than in the
low-TG group [26]. Furthermore, after adjustment for TG levels, the as-
sociation became nonsigniﬁcant in the total samples and was attenuat-
ed in female subjects (Table 4). The contrastive resultswith andwithout
adjustment for TG provide a statistic evidence of the effects of
rs2266788 in plasma TG regulation and CAD incidence, and show that
rs2266788 is a genetic risk factor for CAD mediated through TG levels.
3.2. LD analyses to dissect nearby associations
Numerous SNPs in the 11q23.3 region have been reported to be as-
sociated with TG levels. To gain insight into the LD pattern of
rs2266788 and other SNPs with strong evidence of association, the
data for these SNPs (Table S5) were extracted from 1000 Genomes
Phase I datasets for LD analyses. Strikingly, rs2266788 and multiple
SNPs were in strong LD in CHB population (Fig. 1). A battery of signiﬁ-
cant SNPs, rs1558861, rs10790162, rs964184, rs6589566, rs2075290,
rs2266788, rs2072560, rs651821, and rs662799, virtually represented
the same statistical association signal. In particular, rs2266788 was in
perfect LD with rs2072560, rs2075290, rs6589566, and rs964184. AP value Betaadj (95% CI)⁎ Padj value⁎
1.02 × 10−13 0.049 (0.036–0.062) 5.17 × 10−13
1.08 × 10−07 0.059 (0.038–0.081) 1.01 × 10−07
1.54 × 10−07 0.043 (0.027–0.06) 3.48 × 10−07
1.83 × 10−06 0.05 (0.029–0.071) 4.68 × 10−06
6.85 × 10−09 0.05 (0.033–0.067) 6.60 × 10−09
(adjustment for age and sex in control and case groups; adjustment for age and CAD status
Table 3
Allelic analyses of the association between rs2266788 and CAD by Cochran–Armitage
trend tests.
Sample Cases (C/T)⁎ Controls (C/T)⁎ χ2 Ptrend OR (95% CI)
Total 1000/3124 516/1804 3.378 0.066 1.119 (0.992–1.263)
Females 320/968 246/938 5.94 0.015 1.26 (1.044–1.523)
Males 680/2156 270/866 0.02 0.889 1.012 (0.861–1.189)
OR, odds ratio; CI, conﬁdence interval.
P value b 0.05 is shown in bold.
⁎ Allelic counts in cases or controls.
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CEU (Utah residents with Northern and Western European ancestry
from the CEPH collection) population, and these associations were
poorly dissected in previous studies of Europeans. The polymorphism
rs3135506 (c.56CNG; p.19SerNTry) and other SNPs in LD was absent in
CHB (Fig. 1), and rs3135506 was not in LD with rs2266788 in CEU
(Fig. S3). Thus, rs3135506might be an independent association in pop-
ulations with European ancestry. Likewise, rs2075291 (c.553GNT;
p.185GlyNCys) was not in LD with other SNPs in CHB and was mono-
morphic in CEU.
3.3. Reduced gene expression of the C allele in vivo and in vitro
We examined the APOA5mRNA expression level in normal human
liver samples, and compared the expression among each genotype of
rs2266788. The results showed that the APOA5 gene expression was
lower in samples carrying the C allele, and there was 60% reduction in
the gene expression for CC homozygotes (Fig. 2A).
AEI, which examines difference in transcriptional activity between
two alleles from the same source, prevents interference from trans-
acting regulators or environmental confounders, and improves the sen-
sitivity to identify cis-acting effects even with limited sample size [27].
To survey whether relative expression imbalance occurred between
the two alleles of rs2266788 in human liver samples, we inquired into
heterozygous subjects. Almost a uniform deviation of allelic expression
ratios in mRNA from the ratios in genomic DNA was observed,
demonstrating unequal transcript abundance between the two alleles
(Fig. 2B). The APOA5 expression level from the C allele was signiﬁcantly
lower than that from the T allele (P = 5.15 × 10−5), and the C allele
showed about 70% of the transcriptional activity of the T allele. The dif-
ferential allelic expression strongly suggested a cis-acting effect of this
polymorphism.
In order to further examine whether rs2266788 is a functional vari-
ant leading to alteration of the APOA5mRNA expression, in vitro lucifer-
ase reporter assays were performed. Luciferase reporter vectors
carrying different alleles of the APOA5 3′ UTR were constructedTable 4
Genotypic analyses of the association of rs2266788 with CAD using logistic regression
models.
Sample Adjustment OR (95% CI) P value
Total – 1.121 (0.992–1.267) 0.066
TG 1.092 (0.965–1.235) 0.164
Age, Sex⁎ 1.151 (1.012–1.309) 0.033
Age, Sex⁎, TG 1.101 (0.967–1.255) 0.147
Females – 1.269 (1.047–1.538) 0.015
TG 1.212 (0.998–1.472) 0.053
Age 1.397 (1.139–1.714) 0.001
Age, TG 1.336 (1.087–1.643) 0.006
Males – 1.012 (0.860–1.19) 0.888
TG 0.987 (0.838–1.163) 0.877
Age 1.019 (0.863–1.203) 0.824
Age, TG 0.978 (0.827–1.157) 0.795
OR, odds ratio; CI, conﬁdence interval; TG, triglyceride.
P values b 0.05 are marked in bold.
⁎ The adjustment for sex was excluded in the female and male cohorts.(Fig. 3A), and pairwise comparison of their relative transcriptional activ-
ity was performed separately in BEL-7402, BEL-7405, Huh7 and HepG2
cell lines from human hepatocellular carcinoma. As expected, the plas-
mid with the C allele displayed signiﬁcantly lower luciferase expression
level than the plasmid with the T allele in all cell lines (Fig. 3B). The C
allele also had about 70% of the transcriptional activity of the T allele,
whichwas completely in agreementwith the results of the AEI analysis.
4. Discussion
Results from nuclear families [28] and twin studies [29] indicated a
considerable genetic contribution to the variation in plasma TG levels.
Undoubtedly, the APOA5 gene accounts for a pronounced part of the
contribution. Previous studies offered us a suggestive clue to inquire
into how the genetic effects of the APOA5 gene result in variable plasma
TG levels. The SNP rs2266788 became the promising target to investi-
gate. An understanding of the genetic determinants underlying TG reg-
ulation and the risk of CAD development could prompt the clinic
translation to early prevention and novel therapeutic intervention to
dyslipidemia and CAD.
4.1. The association of rs2266788
In this study, we have provided strong evidence that rs2266788, a
functional variant in 3′UTR of theAPOA5 gene, is signiﬁcantly associated
with plasma TG levels conferring CAD risk in the Han Chinese popula-
tion owing to its regulatory effect on transcription of the APOA5 gene.
We appreciated the potential involvement of the plasma TG-
regulating genetic variant in the CAD pathogenesis, and found that the
TG-raising allele was associated with increased predisposition to CAD.
The results reinforce the understanding that genetic determinants of
TG concentration may be relevant to CAD susceptibility.
Polymorphism rs2266788 was signiﬁcantly associated with plasma
TG levels, not only in the total samples but also in CAD patients, normal
controls, female and male cohort. The minor C allele was strongly asso-
ciated with increased TG concentration. The association and the direc-
tion of the effect have been observed consistently across multiple
population samples of diverse ethnicities [14,15]. The replicable results
suggested that this variant was probably a genetic cause of plasma TG
variation. Thus, we explored themechanism bywhich the variant mod-
ulates TG levels. An association between rs2266788 and the APOA5 gene
expressionwas established. In normal liver tissues, global APOA5mRNA
levels were lower in subjects carrying the C allele and were the lowest
for CC genotype. In subjects heterozygous for rs2266788, obvious AEI
between the two alleles of the APOA5 gene was detected, in that the
gene expression from the same sourcewas lower for the C allele relative
to the T allele. Luciferase assays conﬁrmed a similar result that tran-
scriptional activity was reduced for the C allele in comparison with the
T allele. Therefore, the evidence based on in vivo and in vitro experi-
ments supported rs2266788 might regulate in cis the APOA5mRNA ex-
pression. An association between rs2266788 and CAD incidence was
also identiﬁed in our samples, especially in female cohort with higher
TG levels. The genetic structure in Han Chinese populations across ex-
tensive geographic locations using genome-wide SNPs has been well
constructed, and revealed that geographic matching might be a good
proxy for genetic matching [30]. The subjects in the present study
could be clustered into the central Han subgroup with a high degree
of resemblance according to geographic origin. Therefore, the associa-
tionwith CADwas less likely to be spurious by population stratiﬁcation.
High plasma TG level was supposed to be a predisposing factor for cor-
onary atherosclerosis. An equal increment in TG levels conferred a
higher epidemiological risk for cardiovascular disease in women than
in men [5]. The minor C allele, leading to a decrease in the APOA5
gene expression and an increase in TG level for impaired TG clearance,
was associated with higher CAD risk. This point was reinforced by the
stronger association with CAD in females with higher TG levels and
Fig. 1. LD plot of SNPs with strong evidence of association within the 11q23.3 region in CHB of 1000 Genome Phase I. The strength of pairwise LD is in correspondence with r2 metrics.
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gistic regression analyses (Table 4). Themost recent result from a study
of large-scalemeta-analysis on lipid loci illustrated that the strength of a
SNP effect on TG levels was correlated with the magnitude of its effectFig. 2. APOA5mRNA expression difference in normal human liver samples. (A) The APOA5 exp
normalized toGAPDH. (B) Allele-speciﬁc expression of APOA5 in liver samples. Allelic ratios of rs
in mRNA were normalized to those in DNA.on CAD risk, which genetically suggests that TG levels causally inﬂuence
the risk of CAD [31]. Multiple lines of evidence support a causal associ-
ation of the cis-acting SNP rs2266788with plasma TG levels and CAD in-
cidence for the TG-raising allele conferring a higher CAD risk.ression levels among genotypes of rs2266788. The relative APOA5 expression levels were
2266788weremeasured inmRNA and genomic DNA for heterozygous subjects, and ratios
Fig. 3. Luciferase assay for two alleles of rs2266788 in four cell lines. (A) Schematic diagram of luciferase reporter constructs containing different alleles of the APOA5 3′ UTR. (B) Pair-wise
comparison of relative luciferase activity between two alleles in four cell lines. The luciferase activity of the T allele was set as the reference in each cell lines, and relative values for the C
allele were obtained by normalization to the T allele. The results represent mean ± SD in each cell lines.
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The chromosomal region 11q23.3, harboring the APOA1/C3/A4/A5
gene cluster, produces the strongest association signals in GWAS of
plasma TG levels. In particular, a dense set of SNPs, spanning ~60 kb
APOA1/C3/A4/A5 gene cluster, was reported to be associated with TG
levels. However, strong and complex patterns of LD extension in the
gene cluster bring about obstacles to elucidate the true underlying var-
iants and the corresponding genes responsible for these associations in
the lack of experimental evidence for functional analysis.
Lipoprotein lipase (LPL)was early recognized as the fulcrum of plas-
ma TG metabolism for hydrolyzing TG-rich lipoprotein particles [32].
The liver-expressed APOAV enhances LPL activity, facilitates LPL-
mediated TG clearance, and inhibits the hepatic secretion of very low-
density lipoprotein, the major carrier of TGs [33–35]. On the other
hand, the results from genetically modiﬁed mouse models showed
that apoCIII inhibited LPL-mediated TG hydrolysis [36]. The gene
APOC3 and APOA5, in the same APOA1/C3/A4/A5 lipid gene cluster in
the human genome, play separate but opposing roles in determining
plasma TG concentrations [37]. Common variants of the APOC3 gene
have also been associatedwith TG levels in humans [9]. Thus, an impor-
tant problem is haunting thatwhether theAPOA5 SNPs simply reﬂect LD
with functional variants of APOC3, or whether they stand for indepen-
dent associations. Previous reports proposed a strong LD between
APOA5 rs662799 and APOC3 rs2854117 (−482CNT) [38,39]which inﬂu-
enced TG levels by disrupting the insulin response element of APOC3
[40]. Nevertheless, in the present LD analysis (Fig. 1; Fig. S3), there
was no strong correlation between the APOA5 SNPs with association
and rs2854117, suggesting that APOA5 SNPs rs662799, rs651821 and
rs2266788 could not mark the functional effect of APOC3−482CNT.
The SNP rs964184, in perfect LDwith rs2266788, produced a replica-
ble top-ranked association with plasma TG levels, certain component
traits of metabolic syndrome and CAD risk in large-scale GWAS [6,17,
41,42]. The variant resides in the downstream of a zinc ﬁnger protein
gene ZNF259, which is involved in cell proliferation and signal transduc-
tion [43]. Because of the location and a lack of persuasive evidence from
functional exploration, rs964184 was hardly legitimated as the actualcausative variant. Although an association was found between
rs964184 and serum APOAV protein levels in Mexicans [42], no molec-
ular mechanism of the variant was provided, but still a statistic associa-
tion with the quantity of TG-regulating protein. Two statistically
signiﬁcant SNPs in the APOA5 gene promoter, rs662799 (−1131TNC)
and rs651821 (−3ANG), were in strong LD with rs2266788. Their
position in the gene instinctively makes them relevant to the gene
transcription and translation. A functional E-box binding upstream
stimulatory factors modulated by insulin via the phosphatidylinositol
3-kinase pathway [44], and farnesoid X receptor and peroxisome
proliferator-activated receptorα response elementswere characterized
in the upstreamof the gene [45]. Unfortunately, the two variants did not
residewithin or in proximity to any obvious transcription factor binding
sites. Although a large number of the statistical associations of rs662799
and rs651821 were reported, whether these variants are causative re-
mains unable to come to a deﬁnite conclusion. In assays of individual
variants, rs662799 and rs651821did not signiﬁcantly alter luciferase ac-
tivity, and rs651821 also did not inﬂuence in vitro translation efﬁciency
despite a base change in the Kozak sequence [20]. A more detailed ex-
amination of the diversely combined effects of rs662799, rs651821,
and rs2266788 on luciferase activity showed an interaction among
them, and suggested a driving effect from the combination of
rs651821 and rs2266788 [21]. After resequencing the exons plus
exon/intron boundaries of the APOA5 gene, no other potential common
variants were found that could account for the association of rs662799,
rs651821, or rs2266788 [46]. Therefore, it is reasonable to approve
rs2266788 to be a variant with functional consequence, though interac-
tion with other SNPs cannot be completely excluded. Excitingly, a latest
study uncovered the molecular mechanism for the alteration of the
APOA5 gene expression by this variant. The gene expression was
lowered by the minor C allele creating a potential miRNA binding site
for liver-expressed miR-485-5p [47]. The identiﬁcation of rs2266788-
mediated posttranscriptional regulation of the APOA5 gene supported
the present results.
The coding SNP rs3135506 introduces a nonsynonymous change
from polar amino acid serine to aromatic tryptophan at position −5
from the cleavage site of the APOAV signal peptide. This residue change
2153W. Shou et al. / Biochimica et Biophysica Acta 1842 (2014) 2147–2154was predicted to alter the secondary structure of the signal peptide,
leading to less efﬁcient translocation across the endoplasmic reticulum
[20] and the potential malfunction of APOAV in lipid metabolism [48].
As expected, the Trp-19 allele led to signiﬁcant higher plasma TG levels
than Ser-19 [38]. The absence of polymorphism rs3135506 in Chinese
populations, and the independent association in European populations,
supported the variant as an additional genetic determinant of plasma
TG levels. Another nonsynonymous SNP in the APOA5 gene, rs2075291
(c.553GNT; p.185GlyNCys), was identiﬁed to be associated with TG
regulation and even CAD risk in Chinese populations [26,49,50]. Com-
parison of the LD in CHB (Fig. 1) and CEU (Fig. S3) suggested that
rs2075291 might be an important genetic regulator of TG metabolism.
Consequently, rs2266788, rs3135506 and rs2075291 should represent
separate causative associations in the APOA5 gene.
In conclusion, rs2266788 was strongly associated with plasma TG
levels in Han Chinese population, which was consistent with previous
reports of other ethnic samples. The replicability of this association in
diverse populations suggests this variant having the potential for func-
tional consequence. One urgent challenge is to pinpoint actual causative
variants or reﬁne the candidates from masses of associated SNPs in the
11q23.3 region, for which experimental evidence of function is lacking.
The effect of rs2266788 on the APOA5mRNA expression was supported
through in vivomeasuring difference of the hepatic gene expression and
in vitro luciferase assays. The SNPs in LD with rs2266788 marked an
identical association signal in spite of the possibility of interaction
among them. We have provided strong evidence that functional
rs2266788 is signiﬁcantly associated with plasma TG levels conferring
CAD risk in Han Chinese population owing to its cis-acting effect to the
APOA5 gene expression. Accordingly, this work reasonably prioritized
rs2266788 as a causative variant.
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